In a new study, adding an individualized mRNA-based vaccine to post-surgery pembrolizumab immunotherapy for high-risk melanoma reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. The findings were announced in a presentation at the ESMO (European Society for Medical Oncology) Congress 2026 in Madrid. According to a press release from the Melanoma Institute Australia, positive results in melanoma suggest this personalized approach may ena

Dr. Lee Wheless, photo courtesy Vanderbilt University Medical Centre Dermatologists have recommended the dietary supplement nicotinamide...

Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for...

The immunotherapy medication pembrolizumab, approved for the treatment of stage III and IV melanoma, has been shown to reduce...